Skip to main content

Table 2 Tumour-associated antigens and corresponding CAR-Ts, ADCs or BiTEs

From: Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma

Tumour-associated antigens (targets)

Biological function

Agent

Study phase

Research tumour type

Reference

Tn-MUC1

Sialyl-Tn-MUC1

Alter cancer cell adhesion and motility

5E5 CAR T

Mouse Model

Leukemia, PDAC, Breast cancer

2016, Immunity

B7-H3

T cell co-stimulatory molecule

B7-H3. CAR T

Patient derived xenograft

PDAC, Ovarian cancer, Neuroblastoma

2019, Cancer Cell

Mesothelin

Tumour local invasion and metastasis

MSLN CARs

Phase I

Mesothelioma,

Ovarian carcinoma,

PDAC

NCT02159716

Anetumab ravtansine

Phase I

Mesothelioma,

Ovarian carcinoma,

PDAC, etc

NCT03102320

CEA

Tumour surface biomarker

CEA-CAR-T

Mouse models

Colorectal cancer, Gastric cancer, PDAC

2019, Cancer Medicine

Phase II/III

PDAC

NCT04037241

Mesothelin & CEA

 

dCAR-T

Cell models

PDAC

2018, Journal of Hematology and Oncology

KRAS G12D

HLA-C*08:02

Tumour formation and progression

CTL targeting KRAS G12D

Phase II

Metastatic cancers (Colorectal cancer, Glioblastoma, PDAC, Ovarian cancer, Breast cancer)

2016, New England Journal of Medicine

NCT01174121

HER2/ERBB2

Tumorigenesis and tumour proliferation

Switchable CAR T against HER2

Xenograft model

PDAC

2019, Gut

CART-HER2

Phase I

Biliary tract cancer, PDAC

NCT01935843

DS-8201a

Phase I

Solid tumors

2016, Clinical Cancer Research

CD133

Tumour stem cells marker

CAR T-133

Phase I

Hepatocellular carcinoma, Colorectal carcinoma, PDAC

NCT02541370

PD-1

Immune checkpoint

chPD1 T cells

Mouse model

Solid tumors (melanoma, renal cancer, liver cancer, PDAC, etc.)

2020, Immunology

MUC16

Tumour surface biomarker

DMUC5754A

Phase I

Ovarian cancer, PDAC

NCT01335958

Guanylyl cyclase C

Membrane receptor

MLN0624

Phase II

PDAC

NCT02202785

Glypican-1

Cell surface proteoglycan

GPC-1-ADC

Patient derived xenograft

PDAC

2020, British Journal of Cancer

EpCAM

Cell adhesion

MT110

Phase I

Colorectal cancer, Ovarian cancer, Gastric cancer, Lung cancer, Prostate cancer

NCT00635596

  1. PDAC pancreatic ductal adenocarcinoma; CAR-T chimeric antigen receptor T cells; ADC antibody-drug conjugate; BiTE bispecific T-cell engager; MSLN Mesothelin; CTL cytotoxic T lymphocytes; PD-1 programmed death-1 receptor